Antivirals in the transplant setting

Antiviral Research

Volumn 71, Issue 2-3 SPEC. ISS., 2006, Pages 192-200

  Griffiths, Paul D ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Evidence based treatment; Herpesviruses; Preemptive therapy; Prophylaxis

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; CIDOFOVIR; FOSCARNET; GANCICLOVIR; IMMUNOSUPPRESSIVE AGENT; PRODRUG; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VALACICLOVIR;

ACUTE TOXICITY; ADOPTIVE IMMUNOTHERAPY; ATHEROSCLEROSIS; CANCER; CHICKENPOX; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DRUG SAFETY; ENCEPHALITIS; ENTERITIS; EPSTEIN BARR VIRUS; EVIDENCE BASED PRACTICE; GENITAL ULCER; GRAFT REJECTION; HEPATITIS; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HERPES VIRUS INFECTION; HERPES ZOSTER; HUMAN; HUMAN HERPESVIRUS 6; HUMAN HERPESVIRUS 7; HUMAN HERPESVIRUS 8; INFERTILITY; KAPOSI SARCOMA; LYMPHOPROLIFERATIVE DISEASE; MENINGOENCEPHALITIS; MOUTH ULCER; NEUTROPENIA; NONHUMAN; OPPORTUNISTIC INFECTION; PATHOGENESIS; PNEUMONIA; POSTOPERATIVE COMPLICATION; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; RETINITIS; SHORT SURVEY; TRANSPLANTATION; VARICELLA ZOSTER VIRUS;

ANTIVIRAL AGENTS; EVIDENCE-BASED MEDICINE; HERPESVIRIDAE; HERPESVIRIDAE INFECTIONS; HUMANS; RANDOMIZED CONTROLLED TRIALS; TRANSPLANTATION; TREATMENT OUTCOME;

EID: 33747107727     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2006.04.016     Document Type: Short Survey

References (79)

1. Amon W., and Farrell P.J. Reactivation of Epstein-Barr virus from latency. Rev. Med. Virol. 15 (2005) 149-156
2. Balfour Jr. H.H., Chace B.A., Stapleton J.T., Simmons R.L., and Fryd D.S. A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. N. Engl. J. Med. 320 (1989) 1381-1387
3. Boeckh M., Leisenring W., Riddell S.R., Bowden R.A., Huang M.L., Myerson D., Stevens-Ayers T., Flowers M.E., Cunningham T., and Corey L. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood 101 (2003) 407-414
4. Bowen E.F., Emery V.C., Wilson P., Johnson M.A., Davey C.C., Sabin C.A., Farmer D., and Griffiths P.D. Cytomegalovirus polymerase chain reaction viraemia in patients receiving ganciclovir maintenance therapy for retinitis. AIDS 12 (1998) 605-611
5. Cheeseman S.H., Rubin R.H., Stewart J.A., Tolkoff-Rubin N.E., Cosimi A.B., Cantell K., Gilbert J., Winkle S., Herrin J.T., Black P.H., Russell P.S., and Hirsch M.S. Controlled clinical trial of prophylactic human-leukocyte interferon in renal transplantation. Effects on cytomegalovirus and herpes simplex virus infections. N. Engl. J. Med. 300 (1979) 1345-1349
6. Clark D.A., Nacheva E.P., Leong H.N., Brazma D., Li I.T., Tsao D.H., Buyck U.C., Atkinson L.E., Lawson E.M., Potter I.N., and Griffiths A.D. Transmission of integrated human herpesvirus 6 through stem cell transplantation: implications for laboratory diagnosis. J. Infect. Dis. 193 (2006) 912-916
7. Collins P., and Darby G. Laboratory studies of herpes simplex virus strains resistant to acyclovir. Rev. Med. Virol. 1 (1991) 19-28
8. De Bruyn G., and Limaye A.P. BK virus-associated nephropathy in kidney transplant recipients. Rev. Med. Virol. 14 (2004) 193-205
9. Einsele H., Ehninger G., Hebart H., Wittkowski K.M., Schuler U., Jahn G., Mackes P., Herter M., Klingebiel T., and Loffler J. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood 86 (1995) 2815-2820
10. Einsele H., Hebart H., Kauffmann-Schneider C., Sinzger C., Jahn G., Bader P., Klingebiel T., Dietz K., Loffler J., Bokemeyer C., Muller C.A., and Kanz L. Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection. Bone Marrow Transplant. 25 (2000) 757-763
11. Emery V.C. Prophylaxis for CMV should not now replace pre-emptive therapy in solid organ transplantation. Rev. Med. Virol. 11 (2001) 83-86
12. Emery V.C., Cope A.V., Bowen E.F., Gor D., and Griffiths P.D. The dynamics of human cytomegalovirus replication in vivo. J. Exp. Med. 190 (1999) 177-182
13. Emery V.C., and Griffiths P.D. Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 8039-8044
14. Emery V.C., Hassan-Walker A.F., Burroughs A.K., and Griffiths P.D. Human cytomegalovirus (HCMV) replication dynamics in HCMV-naive and -experienced immunocompromised hosts. J. Infect. Dis. 185 (2002) 1723-1728
15. Freeman R.B., Paya C., Pescovitz M.D., Humar A., Dominguez E., Washburn K., Blumberg E., Alexander B., and Heaton N. Risk factors for cytomegalovirus viremia and disease developing after prophylaxis in high-risk solid-organ transplant recipients. Transplantation 78 (2004) 1765-1773
16. Fryer J.F., Griffiths P.D., Emery V.C., and Clark D.A. Susceptibility of porcine cytomegalovirus to antiviral drugs. J. Antimicrob. Chemother. 53 (2004) 975-980
17. Ganapathy M.E., Huang W., Wang H., Ganapathy V., and Leibach F.H. Valacyclovir: a substrate for the intestinal and renal peptide transporters PEPT1 and PEPT2. Biochem. Biophys. Res. Commun. 246 (1998) 470-475
18. Gane E., Saliba F., Valdecasas G.J., O'Grady J., Pescovitz M.D., Lyman S., and Robinson C.A. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected]. Lancet 350 (1997) 1729-1733
19. Gilbert C., and Boivin G. Discordant phenotypes and genotypes of cytomegalovirus (CMV) in patients with AIDS and relapsing CMV retinitis. AIDS 17 (2003) 337-341
20. Goodrich J.M., Bowden R.A., Fisher L., Keller C., Schoch G., and Meyers J.D. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann. Intern. Med. 118 (1993) 173-178
21. Gottschalk S., Heslop H.E., and Rooney C.M. Adoptive immunotherapy for EBV-associated malignancies. Leukemia Lymphoma 46 (2005) 1-10
22. Gratama J.W., Oosterveer M.A., Zwaan F.E., Lepoutre J., Klein G., and Ernberg I. Eradication of Epstein-Barr virus by allogeneic bone marrow transplantation: implications for sites of viral latency. Proc. Natl. Acad. Sci. U.S.A. 85 (1988) 8693-8696
23. Gratwohl A., Brand R., Frassoni F., Rocha V., Niederwieser D., Reusser P., Einsele H., and Cordonnier C. Cause of death after allogeneic haematopoietic stem cell transplantation (HSCT) in early leukaemias: an EBMT analysis of lethal infectious complications and changes over calendar time. Bone Marrow Transplant. 36 (2005) 757-769
24. Griffiths A., and Coen D.M. An unusual internal ribosome entry site in the herpes simplex virus thymidine kinase gene. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 9667-9672
25. Griffiths P.D., Ait-Khaled M., Bearcroft C.P., Clark D.A., Quaglia A., Davies S.E., Burroughs A.K., Rolles K., Kidd I.M., Knight S.N., Noibi S.M., Cope A.V., Phillips A.N., and Emery V.C. Human herpesviruses 6 and 7 as potential pathogens after liver transplant: prospective comparison with the effect of cytomegalovirus. J. Med. Virol. 59 (1999) 496-501
26. Grundy J.E., Shanley J.D., and Griffiths P.D. Is cytomegalovirus interstitial pneumonitis in transplant recipients an immunopathological condition?. Lancet 2 (1987) 996-999
27. Haque T., Wilkie G.M., Taylor C., Amlot P.L., Murad P., Iley A., Dombagoda D., Britton K.M., Swerdlow A.J., and Crawford D.H. Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells. Lancet 360 (2002) 436-442
28. Hart G.D., and Paya C.V. Prophylaxis for CMV should now replace pre-emptive therapy in solid organ transplantation. Rev. Med. Virol. 11 (2001) 73-81
29. Hill Jr. R.B., Rowlands Jr. D.T., and Rifkind D. Infectious pulmonary disease in patients receiving immunosuppressive therapy for organ transplantation. N. Engl. J. Med. 271 (1964) 1021-1027
30. Hirsch M.S., Schooley R.T., Cosimi A.B., Russell P.S., Delmonico F.L., Tolkoff-Rubin N.E., Herrin J.T., Cantell K., Farrell M.L., Rota T.R., and Rubin R.H. Effects of interferon-alpha on cytomegalovirus reactivation syndromes in renal-transplant recipients. N. Engl. J. Med. 308 (1983) 1489-1493
31. Hodson E.M., Jones C.A., Webster A.C., Strippoli G.F., Barclay P.G., Kable K., Vimalachandra D., and Craig J.C. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials. Lancet 365 (2005) 2105-2115
32. Kalil A.C., Levitsky J., Lyden E., Stoner J., and Freifeld A.G. Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann. Intern. Med. 143 (2005) 870-880
33. Kim W.R., Badley A.D., Wiesner R.H., Porayko M.K., Seaberg E.C., Keating M.R., Evans R.W., Dickson E.R., Krom R.A., and Paya C.V. The economic impact of cytomegalovirus infection after liver transplantation. Transplantation 69 (2000) 357-361
34. Limaye A.P., Corey L., Koelle D.M., Davis C.L., and Boeckh M. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet 356 (2000) 645-649
35. Littler E., Stuart A.D., and Chee M.S. Human cytomegalovirus UL97 open reading frame encodes a protein that phosphorylates the antiviral nucleoside analogue ganciclovir. Nature 358 (1992) 160-162
36. Lonnqvist B., Palmblad J., Ljungman P., Grimfors G., Jarnmark M., Lerner R., Nystrom-Rosander C., and Oberg G. Oral acyclovir as prophylaxis for bacterial infections during induction therapy for acute leukaemia in adults. The Leukemia Group of Middle Sweden. Support. Care Cancer 1 (1993) 139-144
37. Loren A.W., Porter D.L., Stadtmauer E.A., and Tsai D.E. Post-transplant lymphoproliferative disorder: a review. Bone Marrow Transplant. 31 (2003) 145-155
38. Lowance D., Neumayer H.H., Legendre C.M., Squifflet J.P., Kovarik J., Brennan P.J., Norman D., Mendez R., Keating M.R., Coggon G.L., Crisp A., and Lee I.C. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N. Engl. J. Med. 340 (1999) 1462-1470
39. Lui S.F., Ali A.A., Grundy J.E., Fernando O.N., Griffiths P.D., and Sweny P. Double-blind, placebo-controlled trial of human lymphoblastoid interferon prophylaxis of cytomegalovirus infection in renal transplant recipients. Nephrol. Dial. Transplant. 7 (1992) 1230-1237
40. Macdonald P.S., Keogh A.M., Marshman D., Richens D., Harvison A., Kaan A.M., and Spratt P.M. A double-blind placebo-controlled trial of low-dose ganciclovir to prevent cytomegalovirus disease after heart transplantation. J. Heart Lung Transplant. 14 (1995) 32-38
41. Mar E.C., Chiou J.F., Cheng Y.C., and Huang E.S. Human cytomegalovirus-induced DNA polymerase and its interaction with the triphosphates of 1-(2′-deoxy-2′-fluoro-beta-d-arabinofuranosyl)-5-methyluracil, -5-iodocytosine, and -5-methylcytosine. J. Virol. 56 (1985) 846-851
42. Martin D.F., Kuppermann B.D., Wolitz R.A., Palestine A.G., Li H., and Robinson C.A. Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group. N. Engl. J. Med. 340 (1999) 1063-1070
43. Mattes F.M., Hainsworth E.G., Geretti A.M., Nebbia G., Prentice G., Potter M., Burroughs A.K., Sweny P., Hassan-Walker A.F., Okwuadi S., Sabin C., Amooty G., Brown V.S., Grace S.C., Emery V.C., and Griffiths P.D. A randomized, controlled trial comparing ganciclovir to ganciclovir plus foscarnet (each at half dose) for preemptive therapy of cytomegalovirus infection in transplant recipients. J. Infect. Dis. 189 (2004) 1355-1361
44. Merigan T.C., Renlund D.G., Keay S., Bristow M.R., Starnes V., O'Connell J.B., Resta S., Dunn D., Gamberg P., and Ratkovec R.M. A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation. N. Engl. J. Med. 326 (1992) 1182-1186
45. Metselaar H.J., Rothbarth P.H., Brouwer R.M., Wenting G.J., Jeekel J., and Weimar W. Prevention of cytomegalovirus-related death by passive immunization. A double-blind placebo-controlled study in kidney transplant recipients treated for rejection. Transplantation 48 (1989) 264-266
46. Nickeleit V., Klimkait T., Binet I.F., Dalquen P., Del Z.V., Thiel G., Mihatsch M.J., and Hirsch H.H. Testing for polyomavirus type BK DNA in plasma to identify renal-allograft recipients with viral nephropathy. N. Engl. J. Med. 342 (2000) 1309-1315
47. Parravicini C., Olsen S.J., Capra M., Poli F., Sirchia G., Gao S.J., Berti E., Nocera A., Rossi E., Bestetti G., Pizzuto M., Galli M., Moroni M., Moore P.S., and Corbellino M. Risk of Kaposi's sarcoma-associated herpes virus transmission from donor allografts among Italian posttransplant Kaposi's sarcoma patients. Blood 90 (1997) 2826-2829
48. Paya C., Humar A., Dominguez E., Washburn K., Blumberg E., Alexander B., Freeman R., Heaton N., and Pescovitz M.D. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am. J. Transplant. 4 (2004) 611-620
49. Paya C.V., Wilson J.A., Espy M.J., Sia I.G., DeBernardi M.J., Smith T.F., Patel R., Jenkins G., Harmsen W.S., Vanness D.J., and Wiesner R.H. Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant patients: a randomized, placebo-controlled trial. J. Infect. Dis. 185 (2002) 854-860
50. Pescovitz M.D., Rabkin J., Merion R.M., Paya C.V., Pirsch J., Freeman R.B., O'Grady J., Robinson C., To Z., Wren K., Banken L., Buhles W., and Brown F. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob. Agents Chemother. 44 (2000) 2811-2815
51. Prentice H.G., Gluckman E., Powles R.L., Ljungman P., Milpied N., Fernandez Ranada J.M., Mandelli F., Kho P., Kennedy L., and Bell A.R. Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. European Acyclovir for CMV Prophylaxis Study Group. Lancet 343 (1994) 749-753
52. Razonable R.R., Brown R.A., Humar A., Covington E., Alecock E., and Paya C.V. Herpesvirus infections in solid organ transplant patients at high risk of primary cytomegalovirus disease. J. Infect. Dis. 192 (2005) 1331-1339
53. Razonable R.R., and Paya C.V. The impact of human herpesvirus-6 and -7 infection on the outcome of liver transplantation. Liver Transplant. 8 (2002) 651-658
54. Regamey N., Tamm M., Wernli M., Witschi A., Thiel G., Cathomas G., and Erb P. Transmission of human herpesvirus 8 infection from renal-transplant donors to recipients. N. Engl. J. Med. 339 (1998) 1358-1363
55. Reusser P., Einsele H., Lee J., Volin L., Rovira M., Engelhard D., Finke J., Cordonnier C., Link H., and Ljungman P. Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood 99 (2002) 1159-1164
56. Rooney C.M., Loftin S.K., Holladay M.S., Brenner M.K., Krance R.A., and Heslop H.E. Early identification of Epstein-Barr virus-associated post-transplantation lymphoproliferative disease. Br. J. Haematol. 89 (1995) 98-103
57. Rubin R.H. The indirect effects of cytomegalovirus infection on the outcome of organ transplantation. JAMA 261 (1989) 3607-3609
58. Rubin R.H. Preemptive therapy in immunocompromised hosts. N. Engl. J. Med. 324 (1991) 1057-1059
59. Sachs D.H. A knock-out punch?. Nat. Med. 11 (2005) 1271
60. Safrin S., Crumpacker C., Chatis P., Davis R., Hafner R., Rush J., Kessler H.A., Landry B., and Mills J. A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group. N. Engl. J. Med. 325 (1991) 551-555
61. Salzberger B., Bowden R.A., Hackman R.C., Davis C., and Boeckh M. Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of cytomegalovirus disease: risk factors and outcome. Blood 90 (1997) 2502-2508
62. Saral R., Ambinder R.F., Burns W.H., Angelopulos C.M., Griffin D.E., Burke P.J., and Lietman P.S. Acyclovir prophylaxis against herpes simplex virus infection in patients with leukemia. A randomized, double-blind, placebo-controlled study. Ann. Intern. Med. 99 (1983) 773-776
63. Selby P.J., Powles R.L., Easton D., Perren T.J., Stolle K., Jameson B., Fiddian A.P., Tryhorn Y., and Stern H. The prophylactic role of intravenous and long-term oral acyclovir after allogeneic bone marrow transplantation. Br. J. Cancer 59 (1989) 434-438
64. Shirali G.S., Ni J., Chinnock R.E., Johnston J.K., Rosenthal G.L., Bowles N.E., and Towbin J.A. Association of viral genome with graft loss in children after cardiac transplantation. N. Engl. J. Med. 344 (2001) 1498-1503
65. Singh N. Late-onset cytomegalovirus disease as a significant complication in solid organ transplant recipients receiving antiviral prophylaxis: a call to heed the mounting evidence. Clin. Infect. Dis. 40 (2005) 704-708
66. Singh N., Husain S., Carrigan D.R., Knox K.K., Weck K.E., Wagener M.M., and Gayowski T. Impact of human herpesvirus-6 on the frequency and severity of recurrent hepatitis C virus hepatitis in liver transplant recipients. Clin. Transplant. 16 (2002) 92-96
67. Singh N., Wannstedt C., Keyes L., Gayowski T., Wagener M.M., and Cacciarelli T.V. Efficacy of valganciclovir administered as preemptive therapy for cytomegalovirus disease in liver transplant recipients: impact on viral load and late-onset cytomegalovirus disease. Transplantation 79 (2005) 85-90
68. Singh N., Wannstedt C., Keyes L., Wagener M.M., Gayowski T., and Cacciarelli T.V. Indirect outcomes associated with cytomegalovirus (opportunistic infections, hepatitis C virus sequelae, and mortality) in liver-transplant recipients with the use of preemptive therapy for 13 years. Transplantation 79 (2005) 1428-1434
69. Snydman D.R., Werner B.G., Dougherty N.N., Griffith J., Rubin R.H., Dienstag J.L., Rohrer R.H., Freeman R., Jenkins R., and Lewis W.D. Cytomegalovirus immune globulin prophylaxis in liver transplantation. A randomized, double-blind, placebo-controlled trial. The Boston Center for Liver Transplantation CMVIG Study Group. Ann. Intern. Med. 119 (1993) 984-991
70. Talarico C.L., Burnette T.C., Miller W.H., Smith S.L., Davis M.G., Stanat S.C., Ng T.I., He Z., Coen D.M., Roizman B., and Biron K.K. Acyclovir is phosphorylated by the human cytomegalovirus UL97 protein. Antimicrob. Agents Chemother. 43 (1999) 1941-1946
71. Valantine H.A., Gao S.Z., Menon S.G., Renlund D.G., Hunt S.A., Oyer P., Stinson E.B., Brown Jr. B.W., Merigan T.C., and Schroeder J.S. Impact of prophylactic immediate posttransplant ganciclovir on development of transplant atherosclerosis: a post hoc analysis of a randomized, placebo-controlled study. Circulation 100 (1999) 61-66
72. Van Esser J.W., Niesters H.G., Van der H.B., Meijer E., Osterhaus A.D., Gratama J.W., Verdonck L.F., Lowenberg B., and Cornelissen J.J. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood 99 (2002) 4364-4369
73. Wagner H.J., Cheng Y.C., Huls M.H., Gee A.P., Kuehnle I., Krance R.A., Brenner M.K., Rooney C.M., and Heslop H.E. Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood 103 (2004) 3979-3981
74. Wagner H.J., Wessel M., Jabs W., Smets F., Fischer L., Offner G., and Bucsky P. Patients at risk for development of posttransplant lymphoproliferative disorder: plasma versus peripheral blood mononuclear cells as material for quantification of Epstein-Barr viral load by using real-time quantitative polymerase chain reaction. Transplantation 72 (2001) 1012-1019
75. Wagner J.A., Ross H., Hunt S., Gamberg P., Valantine H., Merigan T.C., and Stinson E.B. Prophylactic ganciclovir treatment reduces fungal as well as cytomegalovirus infections after heart transplantation. Transplantation 60 (1995) 1473-1477
76. Wang F.Z., Linde A., Hagglund H., Testa M., Locasciulli A., and Ljungman P. Human herpesvirus 6 DNA in cerebrospinal fluid specimens from allogeneic bone marrow transplant patients: does it have clinical significance?. Clin. Infect. Dis. 28 (1999) 562-568
77. Winston D.J., Ho W.G., Bartoni K., Du M.C., Ebeling D.F., Buhles W.C., and Champlin R.E. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, double-blind trial. Ann. Intern. Med. 118 (1993) 179-184
78. Zerr D.M., Corey L., Kim H.W., Huang M.L., Nguy L., and Boeckh M. Clinical outcomes of human herpesvirus 6 reactivation after hematopoietic stem cell transplantation. Clin. Infect. Dis. 40 (2005) 932-940
79. Zutter M.M., Martin P.J., Sale G.E., Shulman H.M., Fisher L., Thomas E.D., and Durnam D.M. Epstein-Barr virus lymphoproliferation after bone marrow transplantation. Blood 72 (1988) 520-529